Open Label Aripiprazole in the Treatment of Youth with Tic Disorders

Tanya K. Murphy · P. Jane Mutch · Jeannette M. Reid · Paula J. Edge · Eric A. Storch · Michael A. Bengtson +1 more

70 citations0/0 files storedJournal of Child and Adolescent Psychopharmacology

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Obsessive-Compulsive Spectrum Disorders Schizophrenia research and treatment Neurological disorders and treatments

Abstract

BACKGROUND: Primarily safe and efficacious treatments for chronic tic disorders are needed. Also needed are such treatments that target co-morbid conditions. Aripiprazole, a dopaminergic/serotonergic agent with partial agonist properties at the D2 dopamine receptor and 5-hydrdoxytryptamine 1A (5-HT(1A)) receptor and antagonist properties at the 5-HT(2A) receptor, holds promise in both regards. OBJECTIVE: This was an open-label, flexible-dose study to evaluate the safety of aripiprazole in children and adolescents with a primary diagnosis of a chronic tic disorder with/without co-morbid disorder(s). METHOD: Sixteen children (15 males) aged 8-17 years participated in the 6-week trial. Ratings for tic, obsessive compulsive disorder (OCD), attention-deficit/hyperactivity disorder (ADHD), and side effects were administered weekly. Baseline and exit laboratory measures, electrocardiograms (ECGs), weight, and height were obtained. RESULTS: The average daily aripiprazole dose was 3.3 mg (range 1.25-7.5 mg). Significant pre-and posttreatment differences were ascertained for the Yale Global Tic Severity Scale motor (p < or = 0.0001), phonic (p < or = 0.0001), and total tic (p < or = 0.0001) scores. Results of other rating scales suggested significant improvements in co-morbid disorders as well, including OCD, ADHD, and depressive disorders. Although aripiprazole was well tolerated, increases in weight were found. CONCLUSION: In this preliminary open-label trial, aripiprazole was a well-tolerated treatment for tics and co-morbid OCD and ADHD symptoms. Improvements in co-morbid conditions may be secondary to tic reduction or to specific to aripiprazole therapy; however, further study is warranted.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 70 citations exist upstream.

References

1997Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial Reliability and Validity Data 1989The Yale Global Tic Severity Scale: Initial Testing of a Clinician-Rated Scale of Tic Severity 1997Children's Yale-Brown Obsessive Compulsive Scale: Reliability and Validity 1979A Depression Rating Scale for Children 2000Ziprasidone Treatment of Children and Adolescents With Tourette's Syndrome: A Pilot Study 2003Habit Reversal Versus Supportive Psychotherapy for Tourette’s Disorder: A Randomized Controlled Trial 2007Tourette Syndrome and Tic Disorders: A Decade of Progress 2005Habit reversal versus supportive psychotherapy in Tourette's disorder: A randomized controlled trial and predictors of treatment response

Cited by

2012Pharmacological treatment of Gilles de la Tourette syndrome 2012Update on the role of antipsychotics in the treatment of Tourette syndrome 2013Clinical Pharmacology of Dopamine-Modulating Agents in Tourette’s Syndrome

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

Imported from OpenAlex (CC0) — nothing here is generated.